BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial-A European Innovative Therapies for Children with Cancer (ITCC-International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial
Authors
Gray, J.Moreno, L.
Weston, R.
Barone, G.
Rubio, A.
Makin, Guy
Vaidya, S.
Ng, A.
Castel, V.
Nysom, K.
Laureys, G.
Van Eijkelenburg, N.
Owens, C.
Gambart, M.
Pearson, A. D. J.
Laidler, J.
Kearns, P.
Wheatley, K.
Affiliation
University of Southamtpon, SouthamptonIssue Date
2022
Metadata
Show full item recordCitation
Gray J, Moreno L, Weston R, Barone G, Rubio A, Makin G, et al. BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial-A European Innovative Therapies for Children with Cancer (ITCC-International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300005.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.10002Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.10002Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.10002